A treatment of a medical difficulty associated with the formation or presence of a blood clot in a blood vessel, commonly known as thrombectomy. Said treatment may be achieved by introducing and positioning through a single lumen a device capable of macerating, irrigating and aspirating as well as supporting structures proximal to the distal end of said device. Said device is introduced via a blood vessel, and deployed at a treatment site. The macerator is then operated to dislocate thrombus, clot, or other occlusive materials at the target site, the irrigating element is then operated to continue to dislocate thrombus, clot, or other occlusive materials at the target site, and the aspirating element is used to collect and remove the disruptive materials from the target site.

An endovascular treatment mesh device for closing outpouchings by affixing at least one amorphous hydrogel layer expandable in vivo to any or all surfaces of an expandable body comprising at least one material adapted to close said outpouching in the body. The treatment mesh further includes a telescoping center-support bar disposed therein, the center-support bar having at least two telescoping elements that act as reinforcing extension elements to minimize the risk of collapse. Hydrogel is affixed to the surface of the telescoping elements to inhibit retraction. An embodiment wherein the treatment mesh device is a stent.

A multi-layer device is provided that is useful in tissue regeneration, for example, for vascular regeneration, e.g., for use in treatment of a coronary vascular disease, such as for treatment of myocardial infarction. A method of making the device also is provided.

The invention relates to a rod-shaped body (1) comprised of one or more filaments (2) and of a non-ferromagnetic matrix material (3). The matrix material (3) surrounds the filament(s) (1) and/or adheres them to one another. The rod-shaped body is also comprised of a dopant consisting of particles that generate magnetic resonance tomographic artifacts that is introduced into the matrix material (3). Rod-shaped bodies of this type can be used to construct guide wires, catheters and other instruments to be used in minimally invasive surgical interventions.

A drug-eluting product is disclosed comprising an at least partially bioabsorbable element and an active pharmaceutical agent having a morphology, a solubility, and an average particle size which are selected so that the active pharmaceutical agent continues to dissolve during the biodegradation of the bioabsorbable element. The morphology is a crystalline, semi-crystalline or amorphous morphology, the solubility is less than 100 g/ml and the average particle size is grater that about 100 nm.

The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as supports comprising the viral microparticles for the locating the viral microparticles in a wound or in the vicinity of a wound.

The disclosed medical examination glove comprises natural or nitrile rubber latex, and a water soluble singlet oxygen generator. The glove can be manufactured by contacting a glove former with a coagulant solution comprising divalent calcium cations and carbonate particles and a water soluble singlet oxygen generator and then contacting the glove former with a natural or nitrile rubber latex dispersion.

The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group.

A cell adhesive substrate comprising a substratum, on a surface of which a peptide group is immobilized, wherein the peptide group comprises a peptide containing 40% or more and 75% or less of one or two or more of basic amino acid residues selected from the group consisting of lysine, arginine and histidine and 25% or more of one or two or more of hydrophobic amino acid residues selected from the group consisting of leucine, isoleucine, glycine, alanine, valine, phenylalanine, proline, tryptophan and methionine. There is provided a cell adhesive substrate that is unlikely to cause an immune reaction and can maintain a cell adhesion effect for a long time.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.